Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vistusertib - AstraZeneca

Next Previous
Drug Profile

Vistusertib - AstraZeneca

Alternative Names: AZD 2014

Latest Information Update: 08 Mar 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; Cambridge University Hospitals; Massachusetts General Hospital; National Cancer Institute (USA); Netherlands Cancer Institute; NHS Greater Glasgow and Clyde; Queen Mary University of London; Samsung Medical Center; University of Birmingham; University of London; University of Texas M. D. Anderson Cancer Center
  • Class 2 ring heterocyclic compounds; Antineoplastics; Benzamides; Cytostatics; Morpholines; Pyridines; Pyrimidines; Small molecules
  • Mechanism of Action MTORC1 protein inhibitors; MTORC2 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Diffuse large B cell lymphoma; Fallopian tube cancer; Gastric cancer; Glioblastoma; Meningioma; Non-small cell lung cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Renal cancer; Small cell lung cancer; Solid tumours

Most Recent Events

  • 13 Jan 2026 AstraZeneca completes a phase I trial in Breast Cancer (Combination therapy, Metastatic disease, Late-stage disease in the US (NCT01597388) (PO)
  • 12 Apr 2024 AstraZeneca completes a phase-I clinical trials in Solid tumours (Late-stage disease, Second-line therapy or greater) in Japan (PO) (NCT02398747) (JapicCTI152863)
  • 05 Apr 2024 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top